Skip to content

Molecular Pituitary Imaging Using 18F-FET PET

Exploring the Potential for 18F-fluoro-ethyl-tyrosine (18F-FET) to Enable Wider Access to Molecular Imaging for Patients With Pituitary Adenomas (FET-pit-PET Study)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06584123
Acronym
FET-pit-PET
Enrollment
20
Registered
2024-09-04
Start date
2024-09-03
Completion date
2026-12-31
Last updated
2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pituitary Adenoma

Keywords

Molecular pituitary imaging, Functional pituitary imaging, 18F-FET PET

Brief summary

The goal of this single centre pilot study is to explore whether 18F-fluoro-ethyl-tyrosine PET (FET-PET) yields comparable findings to 11C-methionine PET (Met-PET) for the localisation of pituitary tumours.

Detailed description

Up to 20 patients with pituitary adenomas (PA) who have previously undergone 11C-methionine PET (Met-PET) as part of routine clinical care will undergo 18F-fluoroethyltyrosine PET (FET-PET). Patients with newly diagnosed PA or residual/recurrent pituitary tumours following previous treatment will be eligible for recruitment to the study. Quantitative and qualitative analyses will be performed to assess whether MET-PET and FET-PET yield comparable findings in patients with newly diagnosed or recurrent PA.

Interventions

DIAGNOSTIC_TEST18F-Fluoro-ethyl-tyrosine (FET) PET

18F-Fluoro-ethyl-tyrosine PET study of the pituitary

Sponsors

Cambridge University Hospitals NHS Foundation Trust
CollaboratorOTHER
University of Cambridge
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Patient's who have previously undergone 11C-Methionine PET during routine clinical care will be invited to undergo 18F-Fluoro-ethyl-tyrosine PET (FET PET).

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Participant is willing and able to give informed consent for participation in the study * Male or female, age 18 or above * Presence of pituitary adenoma suspected on the basis of clinical/biochemical and/or radiological findings * Previous 11C-Met-PET/CT

Exclusion criteria

* Inability to give informed consent * Pregnancy or suspected pregnancy * Inability to lie supine for 30-60 minutes * Patient body habitus above scanner dimensions * Known allergy to intravenous radiographic contrast agents

Design outcomes

Primary

MeasureTime frameDescription
Maximum Standardized Uptake Values (SUVmax) over pituitary tumour on each of 11C-methionine and 18F-fluoroethyltyrosine PET scans1 dayComparison of maximum Standardized Uptake Values (SUVmax) measured over pituitary tumours on each type of PET scan.

Secondary

MeasureTime frameDescription
Maximum Standardized Uptake Values (SUVmax) over normal pituitary gland and parasellar structures (e.g. cavernous sinuses) on each of 11C-methionine and 18F-fluoroethyltyrosine PET scans1 dayComparison of maximum Standardized Uptake Values (SUVmax) measured over normal pituitary gland and parasellar structures (e.g. cavernous sinuses) on each type of PET scan.

Countries

United Kingdom

Contacts

Primary ContactJames MacFarlane
jm2267@medschl.cam.ac.uk01223 250882

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026